{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:59:49Z","timestamp":1787792389380,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.soncn.2023.151574","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T23:36:10Z","timestamp":1705188970000},"page":"151574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-2401","authenticated-orcid":false,"given":"Natalie","family":"Jackson-Carroll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Shelley","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Whisenant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2023.151574_bib0001","unstructured":"American Cancer Society. Melanoma Skin Cancer Statistics. Cited 2023 Apr 3. https:\/\/www.cancer.org\/cancer\/melanoma-skin-cancer\/about\/key-statistics.html"},{"key":"10.1016\/j.soncn.2023.151574_bib0002","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) Melanoma Staging System: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.soncn.2023.151574_bib0003","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet Br Ed"},{"key":"10.1016\/j.soncn.2023.151574_bib0004","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2023.151574_bib0005","unstructured":"CDC. HRQOL Concepts. Cited 2023 Apr 2. https:\/\/www.cdc.gov\/hrqol\/concept.htm"},{"key":"10.1016\/j.soncn.2023.151574_bib0006","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2021.10.005","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: a systematic review and meta-analysis","volume":"159","author":"Boutros","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpainsymman.2019.03.015","article-title":"Patient-reported outcomes for cancer patients receiving checkpoint inhibitors: opportunities for palliative care\u2014a systematic review","volume":"58","author":"Hall","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.soncn.2023.151574_bib0008","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11764-019-00770-0","article-title":"The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors","volume":"13","author":"Lai-Kwon","year":"2019","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.soncn.2023.151574_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000260","article-title":"Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors","volume":"8","author":"Mamoor","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0010","first-page":"561","article-title":"An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"28","author":"O'Reilly","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0011","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.05.005","article-title":"Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand","volume":"135","author":"Patrinely","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0012","first-page":"3267","article-title":"Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study","volume":"28","author":"Rogiers","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/2192480","article-title":"Neurocognitive function, psychosocial outcome, and health-related quality of life of the first-generation metastatic melanoma survivors treated with ipilimumab","volume":"2020","author":"Rogiers","year":"2020","journal-title":"J Immunol Res"},{"key":"10.1016\/j.soncn.2023.151574_bib0014","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/bjd.17511","article-title":"Uncertain diagnosis and prognosis in advanced melanoma: a qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies","volume":"180","author":"Fox","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.soncn.2023.151574_bib0015","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s11764-019-00803-8","article-title":"A meta-review of qualitative research on adult cancer survivors: current strengths and evidence gaps","volume":"13","author":"Laidsaar-Powell","year":"2019","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.soncn.2023.151574_bib0016","first-page":"1845","article-title":"Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy","volume":"27","author":"Levy","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0017","article-title":"Living in the twilight zone: a qualitative study on the experiences of patients with advanced cancer obtaining long-term response to immunotherapy or targeted therapy","author":"Zwanenburg","year":"2022","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.soncn.2023.151574_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2023.151574_bib0019","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/annonc\/mdw265","article-title":"Effect of nivolumab on health-related quality of life in patients with treatment-na\u00efve advanced melanoma: results from the phase III CheckMate 066 study","volume":"27","author":"Long","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soncn.2023.151574_bib0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejca.2017.08.032","article-title":"Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma","volume":"86","author":"Petrella","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0021","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2016.07.018","article-title":"Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma","volume":"67","author":"Schadendorf","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0022","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2023.151574_bib0023","series-title":"Qualitative Inquiry: The Path of Sciencing","author":"Rizzo","year":"2001"},{"key":"10.1016\/j.soncn.2023.151574_bib0024","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/cncr.23424","article-title":"Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire","volume":"112","author":"Cormier","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1053\/srao.2000.6590","article-title":"Cleeland CS. Cancer-related symptoms","volume":"10","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.soncn.2023.151574_bib0026","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.soncn.2023.151574_bib0027","series-title":"MAXQDA 2022 [computer software]","year":"2021"},{"key":"10.1016\/j.soncn.2023.151574_bib0028","series-title":"Constructing Grounded Theory","author":"Charmaz","year":"2014"},{"key":"10.1016\/j.soncn.2023.151574_bib0029","first-page":"3015","article-title":"Cancer patients\u2019 experiences with immune checkpoint modulators: a qualitative study","volume":"9","author":"Ala-Leppilampi","year":"2020","journal-title":"Cancer Med Malden MA"},{"key":"10.1016\/j.soncn.2023.151574_bib0030","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","article-title":"Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls","volume":"60","author":"Boekhout","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.soncn.2023.151574_bib0031","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2020.03.011","article-title":"Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma","volume":"132","author":"Hemstock","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0032","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.soncn.2023.151574_bib0033","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1097\/NCC.0000000000000683","article-title":"Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: \u201creal-world\u201d data","volume":"43","author":"Milne","year":"2020","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.soncn.2023.151574_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.soncn.2023.151574_bib0035","first-page":"3669","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.soncn.2023.151574_bib0036","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.soncn.2023.151574_bib0037","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1477-7525-8-104","article-title":"Health care providers underestimate symptom intensities of cancer patients: a multicenter European study","volume":"8","author":"Laugsand","year":"2010","journal-title":"Health Qual Life Outcomes"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208123002590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208123002590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:39:55Z","timestamp":1760081995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208123002590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0749208123002590"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2023.151574","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Symptom Experience of Patients with Advanced Melanoma Undergoing Immune Checkpoint Inhibitor (ICI) Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2023.151574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151574"}}